OGD2 Pharma is looking for partners to accelerate its ability to deliver faster better therapies to cancer patients:

• Fundamental research laboratories interested to study the biology of O-acetylated-GD2 in normal cells, cancer cells, and cancer stem cells
• Pre-clinical/clinical research  laboratories interested to evaluate the potential of new therapies targeting O-acetylated-GD2
• Biotechnology companies wishing to leveraging their effector technologies (CAR, ADC, bispecific, etc.) by targeting a highly-specific cancer target